Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00921804 | Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients | PHASE2 | COMPLETED | 296 | — | — | Jun 1, 2009 | May 1, 2010 | Jun 30, 2010 | 3 | United States |
| NCT00986531 | The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics | PHASE1 | COMPLETED | 59 | — | — | Nov 1, 2009 | Oct 1, 2011 | Nov 1, 2011 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD8529 40 mg |
| 2 | PLACEBO_COMPARATOR | Placebo |
| 3 | OTHER | Risperidone 4 mg (2mg on Day 1) |
| Name | Type | Description |
|---|---|---|
| AZD 8529 | DRUG | 40mg oral daily capsule administered as a single dose in the morning for 28 days |
| Risperidone | DRUG | 4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days |
| Placebo to match AZD8529 | DRUG | Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period |
| Placebo to match risperidone | DRUG | Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period |
| AZD8529 | DRUG | 2 capsules by mouth for 3 days |
Inclusion Criteria: * Patient will need to read, understand and sign an informed consent prior to any study specific procedures * Patient will have certain schizophrenia symptoms deemed by the investigator as appropriate for the study entry Exclusion Criteria: * Patients will be excluded based on...